A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.

Trial ID: NCT04755920

Interventional - Phase 2 - Unknown status

This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.

Conditions

• Rectal Neoplasms
• Rectum Cancer
• Colorectal Neoplasms
• Brain Metastases
• Brain Neoplasms
• Brain Diseases
• Brain Cancer
• Brain Tumor
• Intestinal Neoplasms
• Gastrointestinal Neoplasms
• Gastrointestinal Cancer
• Gastrointestinal Disease
• Intestinal Disease

Interventions

• SGM-101

Eligibility

Inclusion criteria

• 1. Signed informed consent prior to any study-mandated procedure;
• 2. Patients aged over 18 years old;
• 3. All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment.
• 4. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
• 5. Diagnosed with brain metastasis of colorectal origin and scheduled for a resection.

Exclusion criteria

• 1. History of any anaphylactic reaction;
• 2. Previous use of SGM-101;
• 3. Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;
• 4. Laboratory abnormalities defined as:
• 1. Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;
• 2. Total bilirubin above 2 times the ULN or;
• 3. Serum creatinine above 1.5 times the ULN or;
• 4. Platelet count below 100 x 109/L or;
• 5. Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);
• 6. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;
• 5. Patients pregnant or breastfeeding;
• 6. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.

Sponsor

Leiden University Medical Center, Medical Center Haaglanden, Surgimab

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows